Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR441344 versus placebo in primary Sjögren's syndrome
2020-000511-77Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing SAR441344 with Placebo (2 arms). Primary endpoint: Change in ESSDAI. Started Sep 2020; status: completed.
02
Drugs
frexalimab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2020-000511-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000511-77.